Slide 1: Acquisition of Melinta Therapeutics
Acquisition of Melinta Therapeutics August 7, 2025 1
Slide 2: Disclaimer
Disclaimer This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Exchange, as amended (the “Exchange Act”), that are subject to risks and uncertainties. Forward-loo
Slide 3: Transaction Overview and Timeline
Transaction Overview and Timeline CorMedix Inc. (“CorMedix”) (NASDAQ: CRMD) has announced a definitive agreement to acquire Melinta Therapeutics, LLC Transaction (“Melinta”), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses Upfront $300mm total upf
Slide 4: Pro Forma Financial Highlights
Pro Forma Financial Highlights Combined portfolio delivers compelling financial profile to deliver growth and fund future business development 2024A Revenue ~$43mm ~$120mm 2025E Revenue $180mm – 200mm $125mm – 135mm Expected Synergies $35mm – 45mm annually 2025E Pro Forma Revenue2 $305mm – 335mm 202
Slide 5: Compelling Transaction Rationale
Compelling Transaction Rationale Establishes a robust commercial hospital / acute care platform that can scale with 1 additional products Diversified revenue base with acute care portfolio consisting of 8 commercial 2 products with potential label expansion opportunities Enhanced financial scale wit
Slide 6: Combined CorMedix and Melinta Business Highlights
Combined CorMedix and Melinta Business Highlights Establishes a robust commercial Multiple “shots-on-goal” for potential hospital / acute care platform that can upside from upcoming regulatory events scale with additional products and label expansion opportunities 11. REZZAYO growth opportunities th
Slide 7: Melinta Overview and Business History
Melinta Overview and Business History Company Overview Product Portfolio Fully integrated and commercial-stage acute care channel focused platform for growth. Established hospital ecosystem focused infrastructure with seasoned customer facing employees 7 commercial products: BAXDELA®, KIMYRSA®, MINO
Slide 8: Combined Product Portfolio
Combined Product Portfolio Creates a diversified portfolio with eight products largely focused in hospital / acute care and two near-term pipeline opportunities Ph III / Product Indication Pre-Clinical Ph I Ph II Commercial Registrational Hemodialysis Commercial Hemodialysis (Pediatric label expansi